Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation

References

• Centers for Disease Control and Prevention. 2010. Available at http://www.cdc.gov/arthritis/basics/rheumatoid.htm
   Google Scholar
• Enbrel® (etanercept) Prescribing Information, Immunex Corporation, Thousand Oaks, CA, USA
   Google Scholar
• Humira® (adalimumab) Prescribing Information, Abbott Laboratories, Abbott Park, IL, USA
   Google Scholar
• Remicade® (infliximab) Prescribing Information, Centocor, Inc., Malvern, PA, USA
   Google Scholar
• Simponi® (golimumab) Prescribing Information, Centocor, Inc., Malvern, PA, USA
   Google Scholar
• Cimzia® (certolizumab pegol) Prescribing Information, UCB, Inc., Smyrna, GA, USA
   Google Scholar
• Pascual-Salcedo D, et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology 2011;50:1445-1452
   PubMed Web of Science ®Google Scholar
• Wolbink GJ, Vis M, Lems W, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:711-15
   PubMed Web of Science ®Google Scholar
• Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007;66:921-6
   PubMed Web of Science ®Google Scholar
• Bartelds GM, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long- term follow-up. JAMA 2011;305:1460-8
   PubMed Web of Science ®Google Scholar
• van de Putte LB, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004;63:508-16
   PubMed Web of Science ®Google Scholar
• Foerder CA, Rogge MC. Enbrel (etanercept). Dev Biol (Basel) 2002;109:99-102
   PubMedGoogle Scholar
• Klareskog L, Moreland L, Cohen S, et al. Efficacy and safety of over 8 years of continuous etanercept therapy in patients with rheumatoid arthritis in North America and Europe. Ann Rheum Dis 2006;65(Suppl II):326
   Google Scholar
• Jamnitski A, Bartelds GM, Nurmohamed MT, et al. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis 2010;70:284-8
   PubMedGoogle Scholar
• Haraoui B, Cameron L, Ouetliet M, et al. Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response. J Rheumatol 2006;33:31-6
   PubMed Web of Science ®Google Scholar
• Finckh A, Dudier J, Wermelinger F, et al. Influence of anti-infliximab antibodies and residual infliximab concentrations on the occurrence of acquired drug resistance to infliximab in rheumatoid arthritis patients. Joint Bone Spine 2010;77:313-18
   PubMed Web of Science ®Google Scholar
• Blom M, Kievit W, Kuper HH, et al. Frequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in daily clinical practice. Arthritis Care Res (Hoboken) 2010;62:1335-41
   PubMed Web of Science ®Google Scholar
• Moots RJ, Haraoui B, Matucci-Cerinic M, et al. Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice. Clin Exp Rheumatol 2011;29:26-34
   PubMed Web of Science ®Google Scholar
• Van Vollenhoven RF, Brannemark S, Klareskog L. Infliximab dosage and infusion frequency in clinical practice: experiences in the Stockholm biologics registry. STURE. Scand J Rheumatol 2007;36:418-23
   PubMed Web of Science ®Google Scholar
• Pavelka K, Jarosova K, Suchy D, et al. Increasing the infliximab dose in rheumatoid arthritis patients: a randomized, double blind study failed to confirm its efficacy. Ann Rheum Dis 2009;68:1285-9
   PubMed Web of Science ®Google Scholar
• Schabert VF, Bruce B, Ferrufino CF, et al. Disability outcomes and dose escalation in rheumatoid arthritis patients treated with tumor necrosis factor blockers: a comparative effectiveness analysis. ISPOR European Congress, Prague, Czech Republic, November 6–9, 2010 (abstract)
   Google Scholar
• Segal SD, Power DJ, Smith DB, et al. Comparative effectiveness analysis of TNF blockers in rheumatoid arthritis (RA) patients in US community practice. EULAR, London, UK, May 25–28, 2011(abstract)
   Google Scholar
• Gu NY, Huang XY, Fox KM, et al. Claims data analysis of dosing and cost of TNF antagonists. Am J Pharm Benefits 2010;2:9
   Google Scholar
• Harrison D, Huang X, Globe D. Dosing patterns and costs of tumor necrosis factor inhibitor use for rheumatoid arthritis. Am J Surg Pathol 2010;67:1281-7
   Google Scholar
• Bullano MF, McNeeley BJ, Yu YF, et al. Comparison of costs associated with the use of etanercept, infliximab, and adalimumab for the treatment of rheumatoid arthritis. Manag Care Interface 2006;19:47-53
   PubMedGoogle Scholar
• Huang X, Ning G, Fox K, et al. Comparison of methods for measuring dose escalation of the subcutaneous TNF antagonists for rheumatoid arthritis patients treated in routine clinical practice. Curr Med Res Opin 2010;26:1637-45
   PubMed Web of Science ®Google Scholar
• Ollendorf D, Kingman D, Hazard R, et al. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population. Clin Ther 2009;31:821-35
   Google Scholar
• Alonso-Ruiz A, Pijoan JI, Ansuategui E, et al. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and meta-analysis of efficacy and safety. BioMed Central Musculoskeletal Disorders 2008;9:52
   PubMed Web of Science ®Google Scholar
• Zintzaras E, Dahabreh IJ, Giannouli S, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens. Clin Ther 2008;30:1939-55
   PubMed Web of Science ®Google Scholar
• Perdriger A. Infliximab in the treatment of rheumatoid arthritis. Biologics 2009;3:183-91
   PubMedGoogle Scholar
• SAS. Version 9.2. Cary (NC): SAS Institute Inc., 2002-2008
   Google Scholar
• Khanna D, Cyhaniuk A, Bedenbaugh A. Use of TNF inhibitors in the US: Utilisation patterns and dose escalation from a retrospective US RA population. EULAR, London, UK, May 25–28, 2011 (abstract)
   Google Scholar